Cancel
Alltrna
See Linkedin
Alltrna Employees
10 people indexed:
-
Anne R. Pariser
VP, Medical and Regulatory Affairs
-
Caroline Kӧhrer
VP, Discovery Platform
-
q0gq2qg7zk@5bx4k63.31y Sign up to see email
-
pf3sps@1vqixp1.bp5 Sign up to see email
-
6xh0bdfu@wu1271e.ksb Sign up to see email
-
Lovisa Afzelius
Founding CEO & Director
-
sgkpdhv@93p44kf.i9i Sign up to see email
-
Noubar Afeyan
Chair of the Board of Directors
-
Theonie Anastassiadis
Co-founder and Chief Innovation Officer
-
yh1491zv@5py48b7.83u Sign up to see email
Alltrna Company Information
Alltrna stands as the world’s inaugural tRNA platform company, dedicated to deciphering tRNA biology and developing tRNA therapeutics. The company’s focus is on the central role of tRNA in translating mRNA into proteins, which is crucial for cellular function. By employing machine learning techniques, Alltrna decodes the unique language of tRNA biology and designs tRNA oligonucleotides with therapeutic properties. The company conducts extensive research through high-throughput proprietary in vitro assays and animal model testing to optimize these tRNA molecules. One of their significant developments is tRNA medicines that can read premature stop codons, offering a potential treatment for diseases caused by genetic mutations. Recently, Alltrna raised $109 million in a Series B funding round, which will further support their efforts to advance tRNA medicines targeting stop codon diseases.
Report inaccurate information
Report inaccurate information
